Herein, we examined the impact of PIK3CA activating mutations on the efficacy of anti-HER2 therapies and explored the therapeutic potential of alpha-selective PI3K pharmacological inhibition in HER2+/PIK3CA mutant breast cancer using pre-clinical in vitro and in vivo models. This evidence concerns the gene ERBB2 and breast cancer.